Anti-IL23A/ IL23/ IL-23 functional antibody

Anti-IL23A/ IL23/ IL-23 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to IL23/IL23A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T06841-Ab-1/ GM-Tg-hg-T06841-Ab-2Anti-Human IL23/IL23A monoclonal antibodyHuman
GM-Tg-rg-T06841-Ab-1/ GM-Tg-rg-T06841-Ab-2Anti-Rat IL23/IL23A monoclonal antibodyRat
GM-Tg-mg-T06841-Ab-1/ GM-Tg-mg-T06841-Ab-2Anti-Mouse IL23/IL23A monoclonal antibodyMouse
GM-Tg-cynog-T06841-Ab-1/ GM-Tg-cynog-T06841-Ab-2Anti-Cynomolgus/ Rhesus macaque IL23/IL23A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T06841-Ab-1/ GM-Tg-felg-T06841-Ab-2Anti-Feline IL23/IL23A monoclonal antibodyFeline
GM-Tg-cang-T06841-Ab-1/ GM-Tg-cang-T06841-Ab-2Anti-Canine IL23/IL23A monoclonal antibodyCanine
GM-Tg-bovg-T06841-Ab-1/ GM-Tg-bovg-T06841-Ab-2Anti-Bovine IL23/IL23A monoclonal antibodyBovine
GM-Tg-equg-T06841-Ab-1/ GM-Tg-equg-T06841-Ab-2Anti-Equine IL23/IL23A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T06841-Ab-1/ GM-Tg-hg-T06841-Ab-2; GM-Tg-rg-T06841-Ab-1/ GM-Tg-rg-T06841-Ab-2;
GM-Tg-mg-T06841-Ab-1/ GM-Tg-mg-T06841-Ab-2; GM-Tg-cynog-T06841-Ab-1/ GM-Tg-cynog-T06841-Ab-2;
GM-Tg-felg-T06841-Ab-1/ GM-Tg-felg-T06841-Ab-2; GM-Tg-cang-T06841-Ab-1/ GM-Tg-cang-T06841-Ab-2;
GM-Tg-bovg-T06841-Ab-1/ GM-Tg-bovg-T06841-Ab-2; GM-Tg-equg-T06841-Ab-1/ GM-Tg-equg-T06841-Ab-2
Products NameAnti-IL23/IL23A monoclonal antibody
Formatmab
Target NameIL23
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IL23 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-573Pre-Made Tildrakizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
    BiosimilarGMP-Bios-ab-347Pre-Made Mirikizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
    BiosimilarGMP-Bios-ab-079Pre-Made Brazikumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
    BiosimilarGMP-Bios-ab-486Pre-Made Risankizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
    BiosimilarGMP-Bios-ab-255Pre-Made Guselkumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
    Target AntigenGM-Tg-g-T06841-Ag-1Recombinant multi-species IL23A/ IL23/ IL-23 protein
    CytokineGM-Tg-g-T06841-Ag-1Interleukin 23, alpha subunit p19 (IL23A) protein
    ORF Viral VectorpGMLP000160human IL23A Lentivirus plasmid
    ORF Viral VectorvGMLP000160human IL23A Lentivirus particle
    ORF Viral VectorpGMLPm000117mouse Il23a Lentivirus plasmid
    ORF Viral VectorvGMLPm000117mouse Il23a Lentivirus particle


    Target information

    Target IDGM-T06841
    Target NameIL23
    Gene ID51561,83430,155140,712627,481110,654423,511022,100034230
    Gene Symbol and SynonymsIL-23,IL-23A,IL23,IL23A,IL23P19,P19,SGRF
    Uniprot AccessionQ9NPF7,Q91Z84,Q64FU1
    Uniprot Entry NameIL23A_HUMAN,IL23A_RAT,IL23A_HORSE
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, INN Index, Cytokine Target
    DiseaseN/A
    Gene EnsemblENSG00000110944
    Target ClassificationN/A

    The target: IL23, gene name: IL23A, also named as IL-23, IL-23A, IL23P19, P19, SGRF. This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.